Table 6 Subgroup analyses. Baseline characteristics of patients who were diagnosed with rectal cancer in Sweden 2014–2018 and underwent surgical resection 2014–2018 LAP, ROBOT and OPEN

Age in year, median (IQR)

70.0 (63.3, 76.5)

69 (62.5, 75.5))

69(62.0, 76.0)

0.316

missing

0

0

2

Male sex

789 (57.0)

1,107 (59.2)

2,425 (63.9)

 < 0.001

ASA^a I-II/ASA^a III-V,

1,075 (77.7)/289 (20.9)

1,406 (75.3)/427 (22.9)

2,594 (68.3)/1,135 (30.0)

 < 0.001

missing

20 (1.4)

34 (1.8)

68 (1.8)

BMI^b, median (IQR)

25.5 (22.9, 28.1)

25.5 (23.0, 28.1)

25.7 (23.0, 28.4)

0.512

missing

14 (1.0)

23 (1.2)

56 (1.5)

Tumour height^c

0.247

 Low, < 5 cm

267 (19.3)

386 (20.7)

800 (21.1)

 Middle, 5–10 cm

486 (35.1)

703 (37.7)

1,447 (38.1)

 High, 10-15 cm

619 (44.8)

769 (41.1)

1,503 (39.6)

 missing

12 (0.9)

9 (0.5)

47 (1.2)

cT stage^d

 < 0.001

 T1-T2

459 (33.2)

575 (30.8)

830 (21.9)

 T3

760 (54.9)

1,025 (54.9)

1,919 (50.5)

 T4

135 (9.8)

232 (12.4)

958 (25.2)

 missing

30 (2.2)

35 (1.9)

90 (2.4)

cN stage^e

 < 0.001

 N0

606 (43.8)

797(42.7)

1,297 (34.1)

 N1-N2

764 (55.2)

1,040 (55.7)

2,409 (63.4)

 missing

14 (1.0)

30 (1.6)

91 (2.4)

cTNM^f

 < 0.001

 I

315 (22.7)

404 (21.6)

553 (14.6)

 II

253 (18.3)

352 (18.8)

643 (16.9)

 III

699 (50.5)

961 (51.5)

2,051 (54.0)

 IV

82 (5.9)

101 (5.4)

432 (11.4)

 missing

35 (2.5)

49 (2.6)

118 (3.1)

Pre-operative treatment

 < 0.001

 No treatment

512 (37.0)

673 (35.9)

1,090 (28.7)

 Radiation only

711 (51.4)

799 (42.8)

1,436 (37.8)

 Radiochemotherapy

154 (11.1)

382 (20.4)

1,216 (32.0

 Chemotherapy only

5 (0.4)

10 (0.5)

45 (1.2)

 missing

2 (0.1)

3 (0.2)

10 (0.3)